Clean Watchlist Candidate

FABIOR

Dermatology · Acne vulgaris (tazarotene foam)

FABIOR carries product and use-code patents, moderate complexity (2/5), and no linked clinical competition (0/5). The listed expiry window is approximately 45 months away. Moderate profile — review patent type and trial activity before handing to IP counsel.

Back to watchlist Contact us about this drug

LOE window

45months

to latest listed patent expiry (February 24, 2030)

Expiry attractiveness: 4/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 3

Complexity score: 2/5

Clinical competition

Score: 0/5

Active trials linked: 0

Phase 2/3 trials: 0

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: TAZAROTENE

Applicant (NDA holder): MAYNE PHARMA LLC

Confidence: Medium

Market context

Therapeutic area: Dermatology

Indication: Acne vulgaris (tazarotene foam)

U.S. market size (est.)< $100M

Estimated U.S. net sales tier. Verify current figures before commercial diligence.